**Supplemental Table 1.** Factors associated with length of survival in group A by univariate analysis

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | Patients, N | Hazard ratio (95% CI) | *p*-value |
| Age | <60 | 79 | 1.000 |  |
|  | ≥60 | 186 | 1.256 (0.963-1.637) | 0.093\* |
| Sex | Female | 131 | 1.000 |  |
|  | Male | 134 | 1.346 (1.054-1.718) | 0.017\* |
| Gastrointestinal cancer | No | 197 | 1.000 |  |
|  | Yes | 68 | 1.343 (1.015-1.776) | 0.039\* |
| Hepatobiliary-pancreatic cancer | No | 201 | 1.000 |  |
|  | Yes | 64 | 0.914 (0.689-1.212) | 0.531 |
| Thoracic cancer | No | 223 | 1.000 |  |
|  | Yes | 42 | 0.852 (0.612-1.186) | 0.343 |
| Central nervous system cancer | No | 263 | 1.000 |  |
|  | Yes | 2 | 0.570 (0.142-2.299) | 0.430 |
| Skin cancer | No | 264 | 1.000 |  |
|  | Yes | 1 | 0.751 (0.105-5.365) | 0.776 |
| Gynecologic cancer | No | 240 | 1.000 |  |
|  | Yes | 25 | 0.693 (0.453-1.058) | 0.089\* |
| Sarcoma | No | 262 | 1.000 |  |
|  | Yes | 3 | 0.762 (0.243-2.389) | 0.642 |
| Urologic cancer | No | 244 | 1.000 |  |
|  | Yes | 21 | 1.058 (0.676-1.655) | 0.806 |
| Breast cancer | No | 249 | 1.000 |  |
|  | Yes | 16 | 1.490 (0.896-2.479) | 0.124 |
| Hematologic cancer | No | 255 | 1.000 |  |
|  | Yes | 19 | 1.065 (0.564-2.012) | 0.846 |
| Head & neck cancer | No | 259 | 1.000 |  |
|  | Yes | 6 | 1.465 (0.651-3.297) | 0.356 |
| Other cancer | No | 258 | 1.000 |  |
|  | Yes | 7 | 1.039 (0.489-2.206) | 0.920 |
| PPS | 70~80% | 14 | 1.000 |  |
|  | 60% | 92 | 1.420 (0.784-2.572) | 0.247 |
|  | 50% | 159 | 2.089 (1.173-3.722) | 0.012\* |

PPS, palliative performance scale.

\* *p*-value < 0.1.

**Supplemental Table 2.** Factors associated with length of survival in group A who survived ≥2 weeks by univariate analysis

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | Patients, N | Hazard ratio (95% CI) | *p*-value |
| Age | <60 | 44 | 1.000 |  |
|  | ≥60 | 89 | 0.971 (0.672-1.404) | 0.877 |
| Sex | Female | 75 | 1.000 |  |
|  | Male | 58 | 1.613 (1.126-2.309) | 0.009\* |
| Type of cancer |  |  |  |  |
| Gastrointestinal | No | 99 | 1.000 |  |
|  | Yes | 34 | 1.453 (0.972-2.171) | 0.069\* |
| Hepatobiliary-pancreatic | No | 99 | 1.000 |  |
|  | Yes | 34 | 0.898 (0.606-1.330) | 0.592 |
| Thoracic | No | 122 | 1.000 |  |
|  | Yes | 11 | 1.140 (0.613-2.120) | 0.678 |
| Central nervous system | No | 124 | 1.000 |  |
|  | Yes | 9 | 0.969 (0.491-1.911) | 0.928 |
| Skin | No | 125 | 1.000 |  |
|  | Yes | 8 | 0.723 (0.295-1.771) | 0.478 |
| Gynecologic | No | 125 | 1.000 |  |
|  | Yes | 8 | 0.821 (0.394-1.712) | 0.599 |
| Sarcoma | No | 124 | 1.000 |  |
|  | Yes | 9 | 0.735 (0.368-1.467) | 0.382 |
| Urologic | No | 127 | 1.000 |  |
|  | Yes | 6 | 0.762 (0.336-1.733) | 0.517 |
| Breast | No | 131 | 1.000 |  |
|  | Yes | 2 | 4.237 (1.025-17.251) | 0.046\* |
| Hematologic | No | 125 | 1.000 |  |
|  | Yes | 8 | 1.020 (0.490-2.123) | 0.958 |
| Head & neck | No | 129 | 1.000 |  |
|  | Yes | 4 | 1.067 (0.392-2.903) | 0.899 |
| Other | No | 130 | 1.000 |  |
|  | Yes | 3 | 0.875 (0.278-2.756) | 0.819 |
| PPS change after 1 week | PPS change ≤ 10% | 89 | 1.000 |  |
|  | PPS change> 10% | 44 | 3.904 (2.568-5.937) | <0.001\* |
| PPS change after 2 weeks | PPS change ≤ 10% | 82 | 1.000 |  |
|  | PPS change> 10% | 51 | 3.191 (2.187-4.655) | <0.001\* |
| Initial PPS | 70-80% | 8 | 1.000 |  |
|  | 60% | 62 | 1.424 (0.599-3.386) | 0.424 |
|  | 50% | 63 | 1.829 (0.771-4.338) | 0.171 |

PPS, palliative performance scale.

\* *p*-value < 0.1.